Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Short term Debt (2021 - 2024)

Standard Biotools (LAB) has disclosed Short term Debt for 7 consecutive years, with $54.8 million as the latest value for Q2 2024.

  • Quarterly Short term Debt rose 1095.35% to $54.8 million in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $54.8 million through Jun 2024, up 1095.35% year-over-year, with the annual reading at $5.0 million for FY2023, N/A changed from the prior year.
  • Short term Debt for Q2 2024 was $54.8 million at Standard Biotools, up from $5.0 million in the prior quarter.
  • The five-year high for Short term Debt was $54.8 million in Q2 2024, with the low at $833000.0 in Q3 2022.
  • Average Short term Debt over 4 years is $11.5 million, with a median of $5.0 million recorded in 2023.
  • The sharpest move saw Short term Debt surged 500.24% in 2023, then soared 1095.35% in 2024.
  • Over 4 years, Short term Debt stood at $6.8 million in 2021, then crashed by 87.82% to $833000.0 in 2022, then soared by 500.24% to $5.0 million in 2023, then soared by 995.66% to $54.8 million in 2024.
  • According to Business Quant data, Short term Debt over the past three periods came in at $54.8 million, $5.0 million, and $5.0 million for Q2 2024, Q4 2023, and Q3 2023 respectively.